mobiflex and Joint-Diseases

mobiflex has been researched along with Joint-Diseases* in 2 studies

Trials

1 trial(s) available for mobiflex and Joint-Diseases

Article	Year
Symptomatic long-term treatment of arthrosis with tenoxicam. European journal of rheumatology and inflammation, 1987, Volume: 9, Issue:2 Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Female; Humans; Joint Diseases; Male; Middle Aged; Piroxicam; Time Factors	1987

Other Studies

1 other study(ies) available for mobiflex and Joint-Diseases

Article	Year
Tenoxicam used as a parenteral formulation for acute pain in rheumatic conditions. Scandinavian journal of rheumatology. Supplement, 1989, Volume: 80 Tenoxicam is a thienothiazine derivative with marked analgesic and anti-inflammatory activities. The parenteral application of tenoxicam is especially suitable for initial therapy in acute and painful rheumatic conditions. The pharmacokinetic behaviour of tenoxicam after i.m., i.v. and p.o. administration did not differ, with the exception that higher plasma concentrations were reached during the first two hours after the parenteral dose. After both i.m. and i.v. application, tenoxicam showed a rapid onset of action, and reliable improvement of pain status. Tenoxicam was well tolerated both systemically and locally. About 10% of all patients experienced adverse events characteristic of non-steroidal anti-inflammatory drugs (NSAIDs). Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Half-Life; Humans; Injections, Intramuscular; Injections, Intravenous; Joint Diseases; Pain; Piroxicam	1989

Article

Year

Tenoxicam used as a parenteral formulation for acute pain in rheumatic conditions.

Scandinavian journal of rheumatology. Supplement, 1989, Volume: 80

Tenoxicam is a thienothiazine derivative with marked analgesic and anti-inflammatory activities. The parenteral application of tenoxicam is especially suitable for initial therapy in acute and painful rheumatic conditions. The pharmacokinetic behaviour of tenoxicam after i.m., i.v. and p.o. administration did not differ, with the exception that higher plasma concentrations were reached during the first two hours after the parenteral dose. After both i.m. and i.v. application, tenoxicam showed a rapid onset of action, and reliable improvement of pain status. Tenoxicam was well tolerated both systemically and locally. About 10% of all patients experienced adverse events characteristic of non-steroidal anti-inflammatory drugs (NSAIDs).

Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Half-Life; Humans; Injections, Intramuscular; Injections, Intravenous; Joint Diseases; Pain; Piroxicam

1989